Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Asparaginase Activity Monitoring in adults with acute lymphoblastic leukemia
2018-003517-17Phase 2Terminated
- Sponsor
- GIMEMA
- Start
- May 2021
- Modality
- Therapeutic Enzymes → Recombinant Proteins and Enzymes, Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pegaspargase and Asparaginase erwinia chrysanthemi in acute lymphoblastic leukemia (ALL), sponsored by GIMEMA. Primary endpoint: Serum asparaginase activity during first two cycles. Started May 2021; status: terminated.
02
Drugs
pegaspargaseAsparaginase erwinia chrysanthemi
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on 2018-003517-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003517-17.